A Single-Center, Double-Masked, Randomized Study Evaluating the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops Compared to Systane® Preservative-Free Eye Drops in the Treatment of the Signs and Symptoms of Dry Eye Disease (DED)
Overview
- Phase
- Not Applicable
- Intervention
- glycerin 0.7%/PEG 400 0.3%
- Conditions
- Dry Eye Disease
- Sponsor
- Calm Water Therapeutics LLC
- Enrollment
- 34
- Locations
- 1
- Primary Endpoint
- Tear Film Break-up Time
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The primary objective is to evaluate the tolerability and efficacy of CWT-f-002 lubricant eye drops in the treatment of the signs and symptoms of dry eye disease.
Detailed Description
In this study CWT-f-002 lubricant eye drop is being evaluated in subjects with dry eye. This OTC eye drop has previously shown promising results in multiple preclinical and clinical settings. The active comparator for this study is Systane (R). Ingredient lists as follows. CWT-f-002: Active Ingredients are glycerin 0.7% and polyethylene glycol 400 0.4%. Inactive ingredients are mannitol, polylysine-graft-polyethylene glycol, sterile water for injection, and sodium phosphate buffer. Systane: Active ingredients are polyethylene glycol 400 0.4% and propylene glycol 0.3%. Inactive ingredients are boric acid, calcium chloride, hydroxypropyl guar, magnesium chloride, potassium chloride, purified water, sodium chloride, zinc chloride. Systane (R) may contain hydrochloric acid and/or sodium hydroxide to adjust pH. Both products are preservative free and supplied in unit dosers.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Be at least 18 years of age
- •Have a reported history of dry eye for at least 6 months
- •Have a Tear Film Breakup Time (TFBUT) measurement of \>1 and \<7 seconds at Visit 1
Exclusion Criteria
- •Known contraindications or sensitivities to the use of the study treatment or any of its components
- •Have a clinically significant slit lamp finding at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters
- •Have a condition (ocular or systemic) that the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the trial
Arms & Interventions
glycerin 0.7%/PEG 400 0.3%
20 patients will receive glycerin 0.7%/PEG 400 0.3% lubricant eye drops three times per day for 28 days.
Intervention: glycerin 0.7%/PEG 400 0.3%
polyethylene glycol 400 0.4%/propylene glycol 0.3%
10 patients will receive polyethylene glycol 400 0.4%/propylene glycol 0.3% lubricant eye drops three times per day for 28 days.
Intervention: polyethylene glycol 400 0.4%/propylene glycol 0.3%
Outcomes
Primary Outcomes
Tear Film Break-up Time
Time Frame: 15 minutes after eye drop instillation
State-of-the-art methodology to assess tear stability.